|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
101,000,000 |
Market
Cap: |
234.32(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$2.05 - $9.48 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 12.4 |
Insider 6 Months : 17 |
Insider 3/6 Months : 29.8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
384,775 |
893,065 |
1,195,129 |
1,425,129 |
Total Buy Value |
$1,196,026 |
$3,497,708 |
$5,896,840 |
$6,207,340 |
Total People Bought |
1 |
1 |
1 |
3 |
Total Buy Transactions |
4 |
13 |
16 |
18 |
Total Shares Sold |
13,010 |
29,603 |
29,603 |
35,804 |
Total Sell Value |
$26,020 |
$112,109 |
$112,109 |
$121,538 |
Total People Sold |
3 |
4 |
4 |
4 |
Total Sell Transactions |
3 |
4 |
4 |
5 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Seyedkazemi Setareh |
CHIEF DEVELOPMENT OFFICER |
|
2025-05-15 |
4 |
S |
$2.00 |
$1,848 |
D/D |
(924) |
13,768 |
|
-13% |
|
Fischer Laurent |
CEO, PRESIDENT AND DIRECTOR |
|
2025-05-15 |
4 |
S |
$2.00 |
$18,252 |
D/D |
(9,126) |
87,488 |
|
-13% |
|
Soparkar Peter |
CHIEF OPERATING OFFICER |
|
2025-05-15 |
4 |
S |
$2.00 |
$5,920 |
D/D |
(2,960) |
39,154 |
|
-13% |
|
Leonard Braden Michael |
|
|
2025-04-23 |
4 |
B |
$2.98 |
$148,950 |
D/D |
50,000 |
191,800 |
0.01 |
-19% |
|
Leonard Braden Michael |
|
|
2025-04-22 |
4 |
B |
$3.00 |
$900,000 |
I/I |
300,000 |
3,057,526 |
0.01 |
-22% |
|
Leonard Braden Michael |
|
|
2025-04-02 |
4 |
B |
$4.04 |
$61,408 |
I/I |
15,209 |
2,757,526 |
0.01 |
-46% |
|
Leonard Braden Michael |
|
|
2025-03-31 |
4 |
B |
$4.38 |
$85,668 |
I/I |
19,566 |
2,742,317 |
0.01 |
-47% |
|
Leonard Braden Michael |
|
|
2025-03-27 |
4 |
B |
$5.19 |
$86,089 |
D/D |
16,593 |
141,800 |
0.01 |
-53% |
|
Leonard Braden Michael |
|
|
2025-03-27 |
4/A |
B |
$5.19 |
$86,089 |
D/D |
16,593 |
141,800 |
0.01 |
- |
|
Leonard Braden Michael |
|
|
2025-03-27 |
4 |
S |
$5.19 |
$86,089 |
D/D |
(16,593) |
141,800 |
|
53% |
|
Leonard Braden Michael |
|
|
2025-03-26 |
4 |
B |
$5.04 |
$102,841 |
D/D |
20,407 |
125,207 |
0.01 |
-54% |
|
Leonard Braden Michael |
|
|
2025-03-20 |
4 |
B |
$5.61 |
$171,767 |
I/I |
30,600 |
2,722,761 |
0.01 |
-59% |
|
Leonard Braden Michael |
|
|
2025-03-19 |
4 |
B |
$4.94 |
$123,390 |
I/I |
25,000 |
2,692,161 |
0.01 |
-57% |
|
Leonard Braden Michael |
|
|
2025-03-18 |
4 |
B |
$4.60 |
$292,418 |
I/I |
62,341 |
2,667,161 |
0.01 |
-53% |
|
Leonard Braden Michael |
|
|
2025-02-28 |
4 |
B |
$4.60 |
$391,015 |
I/I |
85,068 |
2,604,820 |
0.01 |
-51% |
|
Leonard Braden Michael |
|
|
2025-02-27 |
4 |
B |
$4.46 |
$387,094 |
I/I |
86,802 |
2,519,752 |
0.01 |
-47% |
|
Leonard Braden Michael |
|
|
2025-02-26 |
4 |
B |
$4.01 |
$660,979 |
I/I |
164,886 |
2,432,950 |
0.01 |
-45% |
|
Seyedkazemi Setareh |
CHIEF DEVELOPMENT OFFICER |
|
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,125 |
14,692 |
|
- |
|
Ozden Rabia Gurses |
Chief Medical Officer |
|
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,125 |
8,125 |
|
- |
|
Fischer Laurent |
CEO, PRESIDENT AND DIRECTOR |
|
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
96,614 |
|
- |
|
Soparkar Peter |
CHIEF OPERATING OFFICER |
|
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
13,125 |
42,114 |
|
- |
|
Rubinstein Linda M |
CHIEF FINANCIAL OFFICER |
|
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,125 |
19,325 |
|
- |
|
Leonard Braden Michael |
|
|
2024-07-30 |
4 |
B |
$7.15 |
$613,470 |
I/I |
85,800 |
2,268,064 |
0.01 |
-20% |
|
Leonard Braden Michael |
|
|
2024-07-18 |
4 |
B |
$9.11 |
$735,736 |
I/I |
80,718 |
2,182,264 |
0.01 |
-35% |
|
Leonard Braden Michael |
|
|
2024-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
104,800 |
|
-31% |
|
184 Records found
|
|
Page 1 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|